Dana-Farber Cancer Institute's cancer therapy developer raised $182m in an upsized IPO where it floated above its range.

C4 Therapeutics, a US-based small molecule drug developer spun out of the Harvard-affiliated Dana-Farber Cancer Institute, floated in a $182m initial public offering on Friday. The company increased the number of shares in the offering from just over 8.8 million to 9.6 million and priced them at $19.00 each, above the IPO’s $16 to $18…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.